Skip to content

Prediction of Outcomes After Surgery for Unruptured Intracranial Aneurysms

The Prediction of Adverse Events After Microsurgery for Intracranial Unruptured Aneurysms (PRAEMIUM) Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04819074
Acronym
PRAEMIUM
Enrollment
4000
Registered
2021-03-26
Start date
2021-05-20
Completion date
2022-10-01
Last updated
2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneurysm, Brain

Keywords

machine learning, unruptured aneurysm

Brief summary

Accurate preoperative identification of patients at high risk for adverse outcomes would be clinically advantageous, as it would allow enhanced resource preparation, better surgical decision-making, enhanced patient education and informed consent, and potentially even modification of certain modifiable risk factors. The aim of the Prediction of adverse events after microsurgery for intracranial unruptured aneurysms (PRAEMIUM) study is therefore to develop and externally validate a clinically applicable, robust ML-based prediction tool based on multicenter data from a range of international centers.

Detailed description

Introduction Unruptured intracranial aneurysms (UIAs) are incidentally detected at an increasing rate, mostly owing to the rise in availability of non-invasive cranial imaging. Decision-making in UIAs is complex and requires consideration of many risk factors for aneurysm growth and rupture to balance the benefits and risks of treatment versus observation. This is due to: 1) the high morbidity and case fatality inherent to aneurysmal subarachnoid hemorrhage (SAH) 2) the relatively low rupture rate of unruptured aneurysms; 3) the potential morbidity and mortality rate associated with either microsurgical or endovascular treatment. Some consistent risk factors for rupture have been identified, including involvement of the posterior circulation, larger diameter, higher age, and some specific populations such as Japanese and Finnish patients. Many other risk factors have been suggested based on varying levels of evidence. However, it is difficult to integrate this considerable number of factors into a single risk assessment and to present a clear clinical decision making algorithm to patients. A range of scoring systems have been developed and validated to approximate the risk of rupture (PHASES) and growth (ELAPSS) or to balance the risks and benefits of microsurgical treatment versus follow-up imaging directly (UIATS) by integrating some of these risk factors. Still, these scores are focused on predicting rupture events instead of neurological outcome. In addition, they usually are focused on solely one outcome, instead of providing a wide range of objective predictive analytics that may then improve shared decision-making. Machine learning (ML) methods have been extraordinarily effective at integrating many clinical patient variables into one holistic risk prediction tailored to each patient. A previous pilot study has been carried out to assess the feasibility of predicting surgical outcomes after surgery for UIAs in a small single-center sample, and it was found that prediction was feasible with good performance metrics, and the most important factors to be included in such models were also identified. A robust, multicenter, externally validated prediction model or predictive score for surgical outcome after microsurgery for UIAs does not yet exist. Methods Data will be collected by a range of international centers. Overall, the model will be built and publication will be compiled according to the transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) guidelines. Each center will collect their data either retrospectively, or from a prospective registry, or from a prospective registry supplemented by retrospectively collected variables. Data from patients operated from January 1st 2010 and onwards will be eligible for inclusion. Data collection should be completed, and deidentified data should be sent to the sponsor institution. A standardized Excel spreadsheet will be provided by the sponsor. The data will be entered in standardized and anonymized form. This spreadsheet will only contain a study-specific patient number. The data set is anonymized source data that includes clinical data extracted from electronic health records (retrospectively or from a prospective registry of already existing data). The data will be anonymized upon entering them into the PRAEMIUM Excel spreadsheet, after which the patients will be numbered consecutively and there will be no way to trace the data back to individual patients. No identifiable data such as date of birth will be included. Whenever the PRAEMIUM Excel spreadsheet is transferred, it will be encrypted using a password and sent through a secure institutional e-mail server. The password will be sent in a separate e-mail. Some missing data is acceptable, but should be kept to a minimum (i.e. must be \< 10%) Endpoint Definitions Models will be developed for the following three endpoints at discharge: Poor neurological outcome (1), as well as presence of (2) new sensorimotor neurological deficits and (3) any complications (surgical or non-surgical). Neurological outcome was assessed by the modified Rankin scale (mRS), and a favorable neurological outcome was defined as mRS 0, 1, or 2. Complications will be assessed using the modified 2009 Clavien-Dindo grading (CDG), and occurrence of a complication was defined as any deviation from CDG 0.The Clavien-Dindo grading system is a classification of surgical complications: Grad 0 signifying no complication, Grade I identifying complications with any deviation from the normal intra- or postoperative course requiring medical treatment, and so forth. Detailed definitions are provided in the Excel spreadsheet. Surgery-related as well as none-surgery-related complications are counted. In case of multiple complications, only the complication with the highest CDG was counted per patient. Input Feature Definitions All features are measured preoperatively. Recorded baseline variables will include age, gender, maximum aneurysm diameter, anatomical location (artery), total number of aneurysms per patient, if multiple aneurysms were treated during the index session, calcification of the aneurysm wall or neck, aneurysm morphology (saccular, dissecting, fusiform, or other), involvement of critical perforating or branch vessels, and intraluminal thrombosis. In addition, the investigators will capture prior SAH, mRS at admission, prior aneurysm treatment, presence of anticoagulation/antiplatelet therapy preoperatively, and hypertension, as well as American Society of Anesthesiologists (ASA) grading, the PHASES, ELAPSS, and UIATS scores including the UIATS pro-repair and pro-conservative treatment subscores. The unruptured intracranial aneurysm treatment score (UIATS) consists of two subscores: One that represents the strength of recommendation for invasive repair of an unruptured aneurysm, and one that represents the strength of recommendation for conservative management of an unruptured aneurysm. The final overall UIATS score is subsequently calculated as the difference between the two subscores. Also included was the surgical approach: minimally invasive or standard approach, and whether a bypass was performed.

Interventions

PROCEDUREMicrosurgery

Microsurgery for unruptured intracranial aneurysm

Sponsors

Macquarie University, Australia
CollaboratorOTHER
University of Melbourne
CollaboratorOTHER
Kepler University Hospital
CollaboratorOTHER
Medical University Innsbruck
CollaboratorOTHER
General University Hospital, Prague
CollaboratorOTHER
Universitätsklinikum Köln
CollaboratorOTHER
Goethe University
CollaboratorOTHER
University Medical Center Mainz
CollaboratorOTHER
University of Göttingen
CollaboratorOTHER
University Hospital Dresden
CollaboratorOTHER
Charite University, Berlin, Germany
CollaboratorOTHER
Heinrich-Heine University, Duesseldorf
CollaboratorOTHER
University of Roma La Sapienza
CollaboratorOTHER
University of Padova
CollaboratorOTHER
University of Florence
CollaboratorOTHER
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
CollaboratorOTHER
University of Messina
CollaboratorOTHER
Universita di Verona
CollaboratorOTHER
University of Genua, Italy
CollaboratorOTHER
Leiden University Medical Center
CollaboratorOTHER
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
CollaboratorOTHER
UMC Utrecht
CollaboratorOTHER
Burdenko Neurosurgery Institute
CollaboratorOTHER
Sahlgrenska University Hospital
CollaboratorOTHER
University of Bern
CollaboratorOTHER
Barrow Neurological Institute
CollaboratorOTHER
Stanford University
CollaboratorOTHER
Emory University
CollaboratorOTHER
University of Wisconsin, Madison
CollaboratorOTHER
University of California, San Francisco
CollaboratorOTHER
University of Illinois at Chicago
CollaboratorOTHER
Brigham and Women's Hospital
CollaboratorOTHER
Mayo Clinic
CollaboratorOTHER
University of California, Los Angeles
CollaboratorOTHER
Endeavor Health
CollaboratorOTHER
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
CollaboratorOTHER
University of Zurich
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Adult patients (18 or older) * Undergone microsurgical treatment for unruptured intracranial aneurysm * Patients with prior SAH may only be included when surgical treatment occurred at least 4 weeks after ictus. * Treated from January 1st 2010 onwards

Exclusion criteria

* No specific

Design outcomes

Primary

MeasureTime frameDescription
modified Rankin ScaleWithin 24 hours of admission to discharge, assessed up to 30 daysNeurological outcome was assessed by the modified Rankin scale (mRS), and a favorable neurological outcome was defined as mRS 0, 1, or 2. The scale runs from 0 to 5, and higher scores mean a worse outcome.
Sensorimotor neurological deficitsWithin 24 hours of admission to discharge, assessed up to 30 daysAny new sensorimotor neurological deficits after surgery will be captured.
Clavien Dindo Complication GradingWithin 24 hours of admission to discharge, assessed up to 30 daysComplications will be assessed using the modified 2009 Clavien-Dindo grading (CDG), and occurrence of a complication was defined as any deviation from CDG 0. The CDG runs from 0 to 5, and higher scores mean a worse complication.

Countries

Australia, Austria, Czechia, Germany, Italy, Netherlands, Russia, Sweden, Switzerland, United States

Contacts

Primary ContactVictor Staartjes
praemium@usz.ch+41 44 255 2660

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026